# AgomAb Therapeutics NV IPO (AGMB): price, date and first-day trading

> AgomAb Therapeutics NV (AGMB) priced its IPO at $16.00 a share and has traded on Nasdaq since Feb 6, 2026.

Canonical: https://massive.com/quote/agmb/ipo
Data as of: 2026-11-19T00:56:07.702Z (15-minute delayed)
Source: Massive (https://massive.com/docs/llms.txt)

## AGMB price

| Figure | Value |
| --- | --- |
| Price | $5.70 |
| Change from the IPO price | -64.38% |
| Change today | -3.72% |

## How AGMB did against the market

AGMB against the market, from its first trade at 12:35 ET to the last trade of the session.

| Measure | Value |
| --- | --- |
| AGMB from its first trade | +1.36% |
| Against the market (QQQ) | +1.1 pts |

## The IPO scoreboard

AGMB against other big listings: the return from each IPO's own price at the first trade, the close of day 1, day 5, and day 30.

| IPO | Raised | First trade | Day 1 close | Day 5 | Day 30 |
| --- | --- | --- | --- | --- | --- |
| AgomAb Therapeutics NV | $200M | -8.13% | -6.87% | -2.31% | -23.19% |
| Figma '25 | $1.22B | +157.58% | +252.42% | +173.64% | +69.64% |
| Circle '25 | $1.05B | +122.58% | +168.45% | +278.18% | +622.98% |
| Reddit '24 | $748M | +38.24% | +47.97% | +69.90% | +40.32% |
| Arm '23 | $5.23B | +10.00% | +23.76% | +3.63% | -3.06% |
| Klarna '25 | $1.37B | +30.00% | +16.14% | +13.73% | -7.33% |
| CoreWeave '25 | $1.5B | -2.50% | +0.02% | +34.32% | +28.42% |

## The offering

| Term | Value |
| --- | --- |
| Expected price range | $15 to $17 |
| IPO price | $16.00 |
| Shares offered | 12.5M |
| Money raised | $200M |
| Listing date | Feb 6, 2026 |
| Exchange | Nasdaq |
| Security | ADR |

## Where AGMB ranks

The company's market cap against the largest US-listed companies.

| Company | Market cap |
| --- | --- |
| AAPL | $5.12T |
| MSFT | $3.77T |
| NVDA | $3.65T |
| GOOGL | $3.47T |
| AMZN | $2.9T |
| TSM | $1.88T |
| AVGO | $1.69T |
| META | $1.58T |
| TSLA | $1.52T |
| BRK.B | $1.22T |
| AGMB | $286.62M |

## Insider buying and selling after the IPO

From Sep 15, 2026 to Nov 19, 2026, 3 AGMB insiders reported open-market purchases of $503.5K across 6 filings; no open-market sales were filed.

- David R. Epstein, Director: bought $103.5K, filed Nov 6, 2026
- Tim Jasper Knotnerus, Chief Executive Officer: bought $94.4K, filed Oct 7, 2026
- David R. Epstein, Director: bought $88.8K, filed Oct 22, 2026
- David R. Epstein, Director: bought $86.4K, filed Oct 7, 2026
- Pierre Thadee Victor Kemula, Chief Financial Officer: bought $85.9K, filed Oct 7, 2026

Sales made in the offering itself are left out.

[Who traded and when](https://massive.com/quote/agmb/insider-trading.md)

## AGMB news

- [Agomab Announces Results of Annual General Meeting](https://www.globenewswire.com/news-release/2026/05/27/3301675/0/en/Agomab-Announces-Results-of-Annual-General-Meeting.html) · GlobeNewswire Inc. · May 27, 2026
- [Agomab Reports Full Year 2025 Financial Results and Confirms 2026 Outlook](https://www.globenewswire.com/news-release/2026/04/23/3280465/0/en/Agomab-Reports-Full-Year-2025-Financial-Results-and-Confirms-2026-Outlook.html) · GlobeNewswire Inc. · Apr 23, 2026
- [Agomab Receives U.S. Patent for AGMB-447, its Inhaled Lung-restricted Small Molecule Inhibitor of ALK5 in Development for the Treatment of Idiopathic Pulmonary Fibrosis](https://www.globenewswire.com/news-release/2026/03/26/3262841/0/en/Agomab-Receives-U-S-Patent-for-AGMB-447-its-Inhaled-Lung-restricted-Small-Molecule-Inhibitor-of-ALK5-in-Development-for-the-Treatment-of-Idiopathic-Pulmonary-Fibrosis.html) · GlobeNewswire Inc. · Mar 26, 2026
- [Agomab Announces Closing of Initial Public Offering](https://www.benzinga.com/pressreleases/26/02/g50495304/agomab-announces-closing-of-initial-public-offering?utm_source=benzinga_taxonomy&utm_medium=rss_feed_free&utm_content=taxonomy_rss&utm_campaign=channel) · Benzinga · Feb 9, 2026

## FAQ

### What was the AgomAb Therapeutics NV IPO price?

$16.00 a share.

### When did AgomAb Therapeutics NV go public?

AgomAb Therapeutics NV listed on Nasdaq on Feb 6, 2026 under the ticker AGMB.

### How much did the AgomAb Therapeutics NV IPO raise?

$200M, before any underwriters' option.

### How did AgomAb Therapeutics NV open on its first day?

AGMB first traded at $14.70, -8.13% from the IPO price of $16.00.

### How did AGMB close on its first day?

Its last regular-session trade was $14.90, -6.87% from the IPO price of $16.00.

### What was the AGMB first-day trading range?

$12.66 to $15.49 in the regular session.

### How many AGMB shares traded on the first day?

2.24M shares in the regular session.

### How many shares did AgomAb Therapeutics NV sell in its IPO?

12.5M shares.

### How did AGMB do against the market on its first day?

AGMB rose 1.4% from its first trade to the last trade of the session. That is 1.1 points better than the market (QQQ, the Nasdaq-100 ETF).

### What exchange is AGMB listed on?

AgomAb Therapeutics NV lists on Nasdaq under the ticker AGMB.

## Live data

The IPO record and the price come from the Massive API.

- `GET https://api.massive.com/vX/reference/ipos?ticker=AGMB`
- `GET https://api.massive.com/v3/snapshot?ticker.any_of=AGMB`
- `GET https://api.massive.com/v2/aggs/ticker/AGMB/range/5/minute/{date}/{date}`

Requests need a Massive API key. API reference for agents: https://massive.com/docs/llms.txt. Connect an AI agent through the Massive MCP server: https://massive.com/docs/ai-tools.

## Related

- [Markets overview](https://massive.com/quote/index.md)
- [Insider trading](https://massive.com/quote/insider-trading.md)

Nothing here is investment advice. Data and content are provided for informational purposes under the Massive Terms of Service: https://massive.com/terms
